Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Jayachandran, Muthuvel ^a   Sanzo, Antonio ^a,c   Owen, Whyte G ^a,b   Miller, Virginia M ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Almo Collegio Borromeo   (Italy)

Author keywords

17 estradiol; CD40; Conjugated equine estrogen; Leukocytes; Raloxifene

Indexed keywords

CD40 ANTIGEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; MESSENGER RNA; PADGEM PROTEIN; RALOXIFENE; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; LEUKOCYTE; LYMPHOCYTE; MOLECULAR WEIGHT; NEUTROPHIL; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS;

ACTINS; ANIMALS; ANNEXIN A5; ANTIGENS, CD40; BLOOD PLATELETS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FLOW CYTOMETRY; IMMUNOBLOTTING; LIPOPROTEINS; OVARIECTOMY; P-SELECTIN; RALOXIFENE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; SWINE; THROMBOPLASTIN;

EID: 27144493239     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01292.2004     Document Type: Article

References (61)

1. Almus FE, Rao LV, and Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 13: 105-111, 1993.
2. Aune B, Oian P, Omsjo I, and Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood. A beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol 173: 1816-1820, 1995.
3. Bar J, Lahav J, Hod M, Ben-Rafael Z, Weinberger I, and Brosens J. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17β-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost 84: 695-700, 2000.
4. Bar J, Tepper R, Fuchs J, Pardo Y, Goldberger S, and Ovadia J. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 81: 261-264, 1993.
5. Bilsel AS, Onaran N, Moini H, and Emerk K. Long-term effect of 17 β-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC. Thromb Res 99: 173-178, 2000.
6. Brand K, Fowler BJ, Edgington TS, and Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 11: 4743-4738, 1991.
7. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 74: 90-93, 1995.
8. Callander NS, Rao LV, Nordfang O, Sandset PM, Warn-Cramer B, and Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 267: 876-882, 1992.
9. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, and Tremoli E. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 23: 1690-1696, 2003.
10. Caplice N, Mueske C, Kleppe L, and Simari R. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 98: 1051-1057, 1998.
11. Carson SD and Brozna JP. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis 4: 281-292, 1993.
12. Ellis TM, Moser MT, Le PT, Flanigan RC, and Kwon ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 13: 553-558, 2001.
13. Esmon CT. Coagulation and inflammation. J Endotoxin Res 9: 192-198, 2003.
14. Furie B and Furie BC. P-selectin induction of tissue factor biosynthesis and expression. Haemostasis 26: 60-65, 1996.
15. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE, and Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 91: 1952-1958, 1995.
16. Hamano N, Terada N, Maesako K, Numata T, and Konno A. Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 19: 263-269, 1998.
17. Hamik A, Setiadi H, Bu G, McEver RP, and Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 274: 4962-4969, 1999.
18. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, and Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 60: 175-180, 1999.
19. Henkens CM, Bom VJ, Seinen AJ, and van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 73: 402-404, 1995.
20. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, and Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594, 1998.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613, 1998.
22. Ibe BO, Falck JR, Johnson AR, and Campbell WB. Regulation of synthesis of prostacyclin and HETEs in human endothelial cells. Am J Physiol Cell Physiol 256: C1168-C1175, 1989.
23. Jayachandran M, Hayashi T, Sumi D, Iguchi A, and Miller VM. Temporal effects of 17β-estradiol on caveolin-1 mRNA and protein in bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 281: H1327-H1333, 2001.
24. Jayachandran M and Miller VM. Human platelets contain estrogen receptor a, caveolin-1 and estrogen receptor associated proteins. Platelets 14: 75-81, 2003.
25. Jayachandran M and Miller VM. Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets. Am J Physiol Heart Circ Physiol 283: H220-H226, 2002.
26. Jayachandran M, Mukherjee R, Steinkamp T, LaBreche P, Bracamonte MP, Okano H, Owen WG, and Miller VM. Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. Am J Physiol Heart Circ Physiol 288: H2355-H2362, 2005.
27. Jayachandran M, Okano H, Chatrath R, Owen WG, McConnell JP, and Miller VM. Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J Appl Physiol 97: 1445-1452, 2004.
28. Jayachandran M, Owen WG, and Miller VM. Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am J Physiol Heart Circ Physiol 284: H1679-H1685, 2003.
29. Jilma B, Hildebrandt J, Kapiotis S, Wagner OF, Kitzweger E, Mullner C, Monitzer B, Krejcy K, and Eichler HG. Effects of estradiol on circulating P-selectin. J Clin Endocrinol Metab 81: 2350-2355, 1996.
30. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, and Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 188: 180-188, 1999.
31. Kaiser B, Hoppensteadt DA, and Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 10: 1925-1935, 2001.
32. Karnicki K, Owen WG, Miller RS, and McBane RD II. Factors contributing to individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol 22: 1495-1499, 2002.
33. Keller ET, Zhang J, Yao Z, and Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause. J Reprod Immunol 50: 41-55, 2001.
34. Koh KK, Horne MK, and Cannon RO. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 82: 626-633, 1999.
35. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, and Cannon RO III. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336: 683-690, 1997.
36. Leatham EW, Bath PM, Tooze JA, and Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J 73: 10-13, 1995.
37. Luyer MD, Khosla S, Owen WG, and Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86: 3629-3634, 2001.
38. Masuzawa T, Miyaura C, Onoe Y, Kusano K, Ohta H, Nozawa S, and Suda T. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 94: 1090-1097, 1994.
39. Medina KL, Strasser A, and Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95: 2059-2067, 2000.
40. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, and Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 84: 9-14, 2000.
41. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, and Buller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 84: 4-8, 2000.
42. Onoe Y, Miyaura C, Ito M, Ohta H, Nozawa S, and Suda T. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice. J Bone Miner Res 15: 541-549, 2000.
43. Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, and Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 76: 729-734, 1996.
44. Ragni M, Golino P, Cirillo P, Scognamiglio A, Piro O, Esposito N, Battaglia C, Botticella F, Ponticelli P, Ramunno L, and Chiariello M. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 102: 113-117, 2000.
45. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66: 6-15, 1991.
46. Rapaport SI and Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12: 1111-1121, 1992.
47. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, and Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96: 170-175, 2000.
48. Rijhsinghani AG, Thompson K, Bhatia SK, and Waldschmidt TJ. Estrogen blocks early T cell development in the thymus. Am J Reprod Immunol 36: 269-277, 1996.
49. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
50. Schonbeck U and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58: 4-43, 2001.
51. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, and Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 80: 1008-1014, 1998.
52. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, and Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 92: 3323-3330, 1995.
53. Speidel CM, Thronton JD, Meng YY, Eisenberg PR, Edgington TS, and Abendschein DR. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Artery Dis 7: 57-62, 1996.
54. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, Mizuno Y, Oshima S, Saito T, Tsuji I, Kumeda K, Kamikubo Y, and Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 134: 253-259, 1997.
55. Tan KT and Lip GY. Platelets, atherosclerosis and the endothelium: new therapeutic targets? Expert Opin Investig Drugs 12: 1765-1776, 2003.
56. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Buller HR, and Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 84: 15-21, 2000.
57. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, and Peverill RE. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 20: 1404-1409, 2000.
58. Teede HJ, McGrath BP, Turner A, and Majewski H. Effects of oral combined hormone replacement therapy on platelet aggregation in post-menopausal women. Clin Sci (Lond) 100: 207-213, 2001.
59. Thijs A, van Baal WM, van der Mooren MJ, Kenemans P, Drager AM, Huijgens PC, and Stehouwer CD. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest 32: 613-618, 2002.
60. Toschi V, Gallo R, Lettino M, Fallen JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, and Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95: 594-599, 1997.
61. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, and Engelmann B. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 281: 603-609, 2001.